137 related articles for article (PubMed ID: 28079301)
1. Case Study for Lean Management in the Public Sector: Improving Combination Product Review at the Food & Drug Administration.
Rappel MJ; Hunter NL; Alexandrow AI; Hair KO; Sherman RE; Califf RM
Clin Transl Sci; 2017 May; 10(3):124-127. PubMed ID: 28079301
[No Abstract] [Full Text] [Related]
2. Is the Food and Drug Administration safe and effective?
Philipson TJ; Sun E
J Econ Perspect; 2008; 22(1):85-102. PubMed ID: 19728421
[No Abstract] [Full Text] [Related]
3. Working together to enhance the efficiency of medical product development.
Sanhai WR
J Nucl Med; 2008 Jun; 49(6):43N-45N. PubMed ID: 18511823
[No Abstract] [Full Text] [Related]
4. Pharmaceuticals ... should the U.S. Food and Drug Administration be remodeled.
Hosp Health Netw; 1996 Jan; 70(1):17. PubMed ID: 8541919
[No Abstract] [Full Text] [Related]
5. Remarks of the Lead Deputy Commissioner of the Food and Drug Administration.
Friedman MA
Food Drug Law J; 1998; 53(1):19-23. PubMed ID: 11795333
[No Abstract] [Full Text] [Related]
6. Remarks by the Commissioner of Food and Drugs.
Kessler DA
Food Drug Law J; 1996; 51(2):207-15. PubMed ID: 11817358
[No Abstract] [Full Text] [Related]
7. Devising a new approach. Proposed changes to device law aim to boost funding, streamline product review.
Rhea S
Mod Healthc; 2007 May; 37(22):30-1. PubMed ID: 17608125
[No Abstract] [Full Text] [Related]
8. Looking for solid ground along the Critical Path.
Ratner M
Nat Biotechnol; 2006 Aug; 24(8):885-7. PubMed ID: 16900118
[No Abstract] [Full Text] [Related]
9. FDA appointee faces angry, demoralized staff.
Fox JL
Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
[No Abstract] [Full Text] [Related]
10. In Silico Methods for Development of Generic Drug-Device Combination Orally Inhaled Drug Products.
Walenga RL; Babiskin AH; Zhao L
CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):359-370. PubMed ID: 31044532
[TBL] [Abstract][Full Text] [Related]
11. FDA restructures new product review centers.
Bouchie A
Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
[No Abstract] [Full Text] [Related]
12. Combination products regulation at the FDA.
Lauritsen KJ; Nguyen T
Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
[TBL] [Abstract][Full Text] [Related]
13. How are drugs approved? Part 1: the evolution of the Food and Drug Administration.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2008 Jan; 46(1):15-9. PubMed ID: 18251347
[TBL] [Abstract][Full Text] [Related]
14. Avoiding the regulatory capture of the Food and Drug Administration.
Egilman DS; Presler AH; Valentin CS
Arch Intern Med; 2007 Apr; 167(7):732-3. PubMed ID: 17420438
[No Abstract] [Full Text] [Related]
15. FDA embraces risk-management approach.
Fox JL
Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
[No Abstract] [Full Text] [Related]
16. The big gap at the FDA.
Stipp D
Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
[No Abstract] [Full Text] [Related]
17. Teaching the elephant to dance: privatizing the FDA review process.
Price EC
Food Drug Law J; 1996; 51(4):651-76. PubMed ID: 11797734
[No Abstract] [Full Text] [Related]
18. A turbulent year at the agency.
Ratner M
Nat Biotechnol; 2006 Feb; 24(2):145-51. PubMed ID: 16465153
[No Abstract] [Full Text] [Related]
19. The role of the FDA in the national cancer program: friend or foe?
Schein PS; Scheffler B; Carter S
Oncologist; 2003; 8(6):501-6. PubMed ID: 14657526
[No Abstract] [Full Text] [Related]
20. A Food and Drug Administration primer.
Simon LS
Arthritis Rheum; 2006 Feb; 55(1):4-8. PubMed ID: 16463403
[No Abstract] [Full Text] [Related]
[Next] [New Search]
